Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 18Recruiting 4Withdrawn 3Unknown 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 12INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Cancer Non-resectable 1Advanced Esophageal Squamous Cell Cancer 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × irinotecan sucrosofate × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT03732508 2018-11-06

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
30 enrolled
Gastrointestinal

Advanced Esophageal Squamous Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡